Literature DB >> 25081531

HAS2 and CD44 in breast tumorigenesis.

Paraskevi Heldin1, Kaustuv Basu2, Inna Kozlova2, Helena Porsch2.   

Abstract

Metastatic spread of breast cancer cells, facilitated by the epithelial-mesenchymal transition (EMT) process, is responsible for the majority of breast cancer mortality. Increased levels of hyaluronan due to deregulation of hyaluronan-synthesizing enzymes, like HAS2, and expression of CD44, the key receptor for hyaluronan, are correlated to poor outcome of patients with basal-like breast cancer. TGFβ induces HAS2 and CD44, both of which are required in the course of efficient TGFβ-induced EMT processes by mammary epithelial cells. Elucidation of the molecular mechanisms underlying tumor-stroma interactions in breast cancer including the regulation of HAS2 and CD44 expression may contribute to the development of better strategies to treat breast cancer patients.
© 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adhesion receptors; Breast cancer; CD44; EMT; HASes; HYALs; Hyaluronan; Hyaluronan synthesis and degradation; Invasion; Metastasis; Receptors for growth factors and cytokines

Mesh:

Substances:

Year:  2014        PMID: 25081531     DOI: 10.1016/B978-0-12-800092-2.00008-3

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  24 in total

1.  Hyaluronan synthase 2 overexpression is correlated with the tumorigenesis and metastasis of human breast cancer.

Authors:  Peng Li; Tingxiu Xiang; Hongzhong Li; Qianqian Li; Bing Yang; Jing Huang; Xiang Zhang; Yuan Shi; Jinxiang Tan; Guosheng Ren
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 2.  Hyaluronan as a therapeutic target in human diseases.

Authors:  Jiurong Liang; Dianhua Jiang; Paul W Noble
Journal:  Adv Drug Deliv Rev       Date:  2015-11-02       Impact factor: 15.470

Review 3.  Hyaluronan, Inflammation, and Breast Cancer Progression.

Authors:  Kathryn L Schwertfeger; Mary K Cowman; Patrick G Telmer; Eva A Turley; James B McCarthy
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

4.  Novel roles for LIX1L in promoting cancer cell proliferation through ROS1-mediated LIX1L phosphorylation.

Authors:  Satoki Nakamura; Tomoaki Kahyo; Hong Tao; Kiyoshi Shibata; Nobuya Kurabe; Hidetaka Yamada; Kazuya Shinmura; Kazunori Ohnishi; Haruhiko Sugimura
Journal:  Sci Rep       Date:  2015-08-27       Impact factor: 4.379

5.  Proteoglycans/glycosaminoglycans: from basic research to clinical practice.

Authors:  George Tzanakakis; Ilona Kovalszky; Paraskevi Heldin; Dragana Nikitovic
Journal:  Biomed Res Int       Date:  2014-12-21       Impact factor: 3.411

6.  Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis.

Authors:  Hanxiao Xu; Yijun Tian; Xun Yuan; Yu Liu; Hua Wu; Qian Liu; Gen Sheng Wu; Kongming Wu
Journal:  Onco Targets Ther       Date:  2016-01-21       Impact factor: 4.147

7.  The deubiquitinating enzymes USP4 and USP17 target hyaluronan synthase 2 and differentially affect its function.

Authors:  M Mehić; V K de Sa; S Hebestreit; C-H Heldin; P Heldin
Journal:  Oncogenesis       Date:  2017-06-12       Impact factor: 7.485

8.  The molecular underpinning of geminin-overexpressing triple-negative breast cancer cells homing specifically to lungs.

Authors:  Eman Sami; Danielle Bogan; Alfredo Molinolo; Jim Koziol; Wael M ElShamy
Journal:  Cancer Gene Ther       Date:  2021-03-15       Impact factor: 5.987

9.  Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine.

Authors:  Di Wu; Jing Wang; Yunlang Cai; Mulan Ren; Yuxia Zhang; Fangfang Shi; Fengshu Zhao; Xiangfeng He; Meng Pan; Chunguang Yan; Jun Dou
Journal:  J Ovarian Res       Date:  2015-10-24       Impact factor: 4.234

10.  Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling.

Authors:  D J Junk; B L Bryson; J M Smigiel; N Parameswaran; C A Bartel; M W Jackson
Journal:  Oncogene       Date:  2017-03-13       Impact factor: 8.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.